Evidence map›Paper›PMID 30787606›Full record

ArticleInternational journal of nanomedicine2019

Controlled-releasing hydrogen sulfide donor based on dual-modal iron oxide nanoparticles protects myocardial tissue from ischemia-reperfusion injury.

Wenshuo Wang, Huan Liu, Yuntao Lu, Xiaole Wang, Bohan Zhang, Shuo Cong, Yun Zhao, Minbiao Ji, Hongyue Tao, Lai Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  6. Nanotechnology for cardiovascular diseases.Innovation (Cambridge (Mass.)) · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. HPharmacological research · 2020
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenshuo WangDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.
Huan LiuDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.
Yuntao LuDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.
Xiaole WangDepartment of Radiology, Second People's Hospital of Nantong City, Nantong 226002, Jiangsu, China.
Bohan ZhangState Key Laboratory of Surface Physics and Department of Physics, Fudan University, Shanghai 200433, China, minbiaoj@fudan.edu.cn.
Shuo CongDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.
Yun ZhaoDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.
Minbiao JiState Key Laboratory of Surface Physics and Department of Physics, Fudan University, Shanghai 200433, China, minbiaoj@fudan.edu.cn.
Hongyue TaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai 200040, China.
Lai WeiDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China, wei.lai@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHydrogen sulfide (H

methodsThe current study describes the development of mesoporous iron oxide nanoparticles (MIONs) which were loaded with diallyl trisulfide (DATS), a H

resultsThe synthesized MIONs were characterized with excellent mesoporosity and a narrow size distribution, which enabled them to slow down the release of H

conclusionThe sustained-release pattern and excellent biocompatibility make DATS-MIONs a promising H

Indexed as

Allyl CompoundsAnimalsCardiotonic AgentsCell LineDelayed-Action PreparationsFerric CompoundsHeartHomeostasisHydrogen SulfideMaleMiceMyocardial IschemiaMyocardial Reperfusion InjuryMyocardiumNanoparticlesSulfidesAllyl CompoundsCardiotonic AgentsDelayed-Action Preparationsdiallyl trisulfideFerric Compoundsferric oxideHydrogen SulfideSulfidesbiocompatibilitybiodegenerationporous structuresteady release

Identifiers

PMID30787606
PMCPMC6363493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.